Original paper
Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study
Abstract
IL-23-inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant. to indirectly compare the effectiveness, safety and tolerability of guselkumab and risankizumab in real world practice. An Italian single-center retrospective cohort study enrolling moderate-to-severe psoriasis patients from September...
Paper Details
Title
Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study
Published Date
Nov 20, 2021
Journal
Volume
35
Issue
1